Select publications

Andre T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract

Arkenau HT et al. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis. Proc ASCO 2004;Abstract 3546.

Cassidy J et al. Improved safety of capecitabine versus bolus 5-fluorouracil/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study). ASCO Gastrointestinal Cancers Symposium 2004;Abstract 219.

Cassidy J et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22(11):2084-91. Abstract

Gray RG et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc ASCO 2004;Abstract 3501.

Grothey A et al. Capecitabine/irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active secondline protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study. Proc ASCO 2004;Abstract 3534.

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

Lopez-Gomez L et al. XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC). Proc ASCO 2004;Abstract 3688.

Lopez-Vivanco G et al. Combination of oxaliplatin and capecitabine (CAPOX) in first and second-line treatment for metastatic colorectal carcinoma (MCRC). Proc ASCO 2004;Abstract 3701.

Ppeiffer P et al. Phase II study of short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) in patients with progressive colorectal cancer after irinotecan and 5-fluorouracil (FU) treatment. Proc ASCO 2004;Abstract 3562.

Scheithauer W et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003;14(12):1735-43. Abstract

Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22(2):229-37. Abstract

Twelves C et al. XELOX (capecitabine plus oxaliplatin), a safe and active first-line regimen for elderly patients with metastatic colorectal cancer (MCRC): Post-hoc analysis of a large phase II study. Proc ASCO 2004;Abstract 3555.

Van Cutsem E et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19(21):4097-106. Abstract

Van Cutsem E et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90(6):1190-7. Abstract